Refining MDR-TB Treatment (T) Regimens (R) for Ultra(U) Short(S) Therapy(T)-PLUS

NCT04717908 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

89

Enrollment

OTHER

Sponsor class

Conditions

Multidrug Resistant Tuberculosis

Interventions

DRUG: Bedaquiline
DRUG: Pyrazinamide
DRUG: Linezolid
DRUG: Cycloserine
DRUG: Clofazimine

Sponsor

Huashan Hospital